|
1
|
Lu K, Chen N, Zhou XX, Ge XL, Feng LL, Li
PP, Li XY, Geng LY and Wang X: The STAT3 inhibitor WP1066
synergizes with vorinostat to induce apoptosis of mantle cell
lymphoma cells. Biochem Biophys Res Commun. 464:292–298. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gelebart P, Anand M, Armanious H, Peters
AC, Bard J Dien, Amin HM and Lai R: Constitutive activation of the
Wnt canonical pathway in mantle cell lymphoma. Blood.
112:5171–5179. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hoffmeyer K, Raggioli A, Rudloff S, Anton
R, Hierholzer A, Del Valle I, Hein K, Vogt R and Kemler R:
Wnt/β-catenin signaling regulates telomerase in stem cells and
cancer cells. Science. 336:1549–1554. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang LQ, Wong KY, Rosèn A and Chim CS:
Epigenetic silencing of tumor suppressor miR-3151 contributes to
Chinese chronic lymphocytic leukemia by constitutive activation of
MADD/ERK and PIK3R2/AKT signaling pathways. Oncotarget.
6:44422–44436. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Queirós AC, Beekman R, Vilarrasa-Blasi R,
Duran-Ferrer M, Clot G, Merkel A, Raineri E, Russiñol N, Castellano
G, Beà S, et al: Decoding the DNA methylome of mantle cell lymphoma
in the light of the entire B cell lineage. Cancer Cell. 30:806–821.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang L, Shalek AK, Lawrence M, Ding R,
Gaublomme JT, Pochet N, Stojanov P, Sougnez C, Shukla SA, Stevenson
KE, et al: Somatic mutation as a mechanism of Wnt/β-catenin pathway
activation in CLL. Blood. 124:1089–1098. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huang A, Yue D, Liao D, Cheng L, Ma J, Wei
Y, Tong A and Cheng P: Survivin T34A increases the therapeutic
efficacy of arsenic trioxide in mouse hepatocellular carcinoma
models. Oncol Rep. 36:3283–3290. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Falchi L, Verstovsek S, Ravandi-Kashani F
and Kantarjian HM: The evolution of arsenic in the treatment of
acute promyelocytic leukemia and other myeloid neoplasms: Moving
toward an effective oral, outpatient therapy. Cancer.
122:1160–1168. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lo-Coco F, Avvisati G, Vignetti M, Thiede
C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona
E, et al: Gruppo Italiano Malattie Ematologiche dell'Adulto;
German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance
Leukemia: Retinoic acid and arsenic trioxide for acute
promyelocytic leukemia. N Engl J Med. 369:111–121. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aldoss I, Mark L, Vrona J, Ramezani L,
Weitz I, Mohrbacher AM and Douer D: Adding ascorbic acid to arsenic
trioxide produces limited benefit in patients with acute myeloid
leukemia excluding acute promyelocytic leukemia. Ann Hematol.
93:1839–1843. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Martelli MP, Gionfriddo I, Mezzasoma F,
Milano F, Pierangeli S, Mulas F, Pacini R, Tabarrini A, Pettirossi
V, Rossi R, et al: Arsenic trioxide and all-trans retinoic acid
target NPM1 mutant oncoprotein levels and induce apoptosis in
NPM1-mutated AML cells. Blood. 125:3455–3465. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bejanyan N, Tiu RV, Raza A, Jankowska A,
Kalaycio M, Advani A, Chan J, Saunthararajah Y, Mooney L,
Maciejewski JP, et al: A phase 2 trial of combination therapy with
thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid
(TADA) in patients with overlap myelodysplastic/myeloproliferative
neoplasms (MDS/MPN) or primary myelofibrosis (PMF). Cancer.
118:3968–3976. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sharma M, Khan H, Thall PF, Orlowski RZ,
Bassett RL Jr, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, et al:
A randomized phase 2 trial of a preparative regimen of bortezomib,
high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer.
118:2507–2515. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dreyling M, Thieblemont C, Gallamini A,
Arcaini L, Campo E, Hermine O, Kluin-Nelemans JC, Ladetto M, Le
Gouill S, Iannitto E, et al: ESMO Consensus conferences: guidelines
on malignant lymphoma. part. 2:marginal zone lymphoma, mantle cell
lymphoma, peripheral T–cell lymphoma. Ann Oncol 24: 857–877.
2013.
|
|
15
|
Zhang S, Ma C, Pang H, Zeng F, Cheng L,
Fang B, Ma J, Shi Y, Hong H, Chen J, et al: Arsenic trioxide
suppresses cell growth and migration via inhibition of miR-27a in
breast cancer cells. Biochem Biophys Res Commun. 469:55–61. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Z, Liu H, Zhou H, Zhu X, Zhao Z, Chi
X, Shan H and Gao J: A facile route to core-shell nanoparticulate
formation of arsenic trioxide for effective solid tumor treatment.
Nanoscale. 8:4373–4380. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chou WC, Hawkins AL, Barrett JF, Griffin
CA and Dang CV: Arsenic inhibition of telomerase transcription
leads to genetic instability. J Clin Invest. 108:1541–1547. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Roboz GJ, Dias S, Lam G, Lane WJ, Soignet
SL, Warrell RP Jr and Rafii S: Arsenic trioxide induces dose- and
time-dependent apoptosis of endothelium and may exert an
antileukemic effect via inhibition of angiogenesis. Blood.
96:1525–1530. 2000.PubMed/NCBI
|
|
19
|
Zhou L, Hou J, Fu W, Wang D, Yuan Z and
Jiang H: Arsenic trioxide and 2-methoxyestradiol reduce
beta-catenin accumulation after proteasome inhibition and enhance
the sensitivity of myeloma cells to Bortezomib. Leuk Res.
32:1674–1683. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kühnl A, Valk PJ, Sanders MA, Ivey A,
Hills RK, Mills KI, Gale RE, Kaiser MF, Dillon R, Joannides M, et
al: Downregulation of the Wnt inhibitor CXXC5 predicts a better
prognosis in acute myeloid leukemia. Blood. 125:2985–2994. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mathur R, Sehgal L, Braun FK, Berkova Z,
Romaguerra J, Wang M, Rodriguez MA, Fayad L, Neelapu SS and
Samaniego F: Targeting Wnt pathway in mantle cell
lymphoma-initiating cells. J Hematol Oncol. 8:632015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zheng L, Jiang H, Zhang ZW, Wang KN, Wang
QF, Li QL and Jiang T: Arsenic trioxide inhibits viability and
induces apoptosis through reactivating the Wnt inhibitor secreted
frizzled related protein-1 in prostate cancer cells. Onco Targets
Ther. 9:885–894. 2016.PubMed/NCBI
|
|
23
|
Mizuno S, Chijiwa T, Okamura T, Akashi K,
Fukumaki Y, Niho Y and Sasaki H: Expression of DNA
methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in
acute and chronic myelogenous leukemia. Blood. 97:1172–1179. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Haas BW, Filkowski MM, Cochran RN, Denison
L, Ishak A, Nishitani S and Smith AK: Epigenetic modification of
OXT and human sociability. Proc Natl Acad Sci USA. 113:pp.
E3816–E3823. 2016; View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Khaleghian A, Ghaffari SH, Ahmadian S,
Alimoghaddam K and Ghavamzadeh A: Metabolism of arsenic trioxide in
acute promyelocytic leukemia cells. J Cell Biochem. 115:1729–1739.
2014. View Article : Google Scholar : PubMed/NCBI
|
